OC
HQL

Oppenheimer & Co’s abrdn Life Sciences Investors HQL Stock Holding History

Oppenheimer & Co’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$285K Buy
17,494
+6,504
+59% +$109K ﹤0.01% 1424
2025
Q4 		$184K Buy
10,990
+506
+5% +$8.5K ﹤0.01% 1441
2025
Q3 		$163K Sell
10,484
-19,149
-65% -$262K ﹤0.01% 1575
2025
Q2 		$380K Buy
29,633
+920
+3% +$11.3K 0.01% 1250
2025
Q1 		$364K Buy
28,713
+9,115
+47% +$123K 0.01% 1193
2024
Q4 		$257K Hold
19,598
– – ﹤0.01% 1344
2024
Q3 		$296K Sell
19,598
-4,588
-19% -$69.4K ﹤0.01% 1237
2024
Q2 		$343K Buy
24,186
+5,772
+31% +$78.1K 0.01% 1141
2024
Q1 		$251K Buy
18,414
+814
+5% +$11.3K ﹤0.01% 1245
2023
Q4 		$237K Hold
17,600
– – ﹤0.01% 1225
2023
Q3 		$219K Buy
17,600
+389
+2% +$5.12K ﹤0.01% 1239
2023
Q2 		$233K Buy
17,211
+386
+2% +$5.33K ﹤0.01% 1242
2023
Q1 		$234K Buy
16,825
+401
+2% +$5.73K 0.01% 1206
2022
Q4 		$233K Buy
16,424
+22
+0.1% +$319 0.01% 1183
2022
Q3 		$225K Buy
16,402
+357
+2% +$5.33K 0.01% 1171
2022
Q2 		$228K Buy
16,045
+392
+3% +$5.92K ﹤0.01% 1213
2022
Q1 		$259K Buy
15,653
+368
+2% +$6.33K ﹤0.01% 1260
2021
Q4 		$295K Buy
15,285
+223
+1% +$4.49K 0.01% 1229
2021
Q3 		$313K Buy
15,062
+391
+3% +$8.37K 0.01% 1209
2021
Q2 		$314K Buy
14,671
+280
+2% +$5.65K 0.01% 1220
2021
Q1 		$284K Sell
14,391
-114
-0.8% -$2.35K 0.01% 1203
2020
Q4 		$286K Buy
14,505
+282
+2% +$5.21K 0.01% 1104
2020
Q3 		$250K Sell
14,223
-10,679
-43% -$191K 0.01% 1065
2020
Q2 		$447K Sell
24,902
-447
-2% -$7.66K 0.01% 841
2020
Q1 		$380K Buy
25,349
+1,640
+7% +$26.9K 0.01% 823
2019
Q4 		$413K Buy
23,709
+231
+1% +$3.79K 0.01% 911
2019
Q3 		$355K Sell
23,478
-6,782
-22% -$109K 0.01% 926
2019
Q2 		$510K Buy
30,260
+651
+2% +$10.7K 0.01% 798
2019
Q1 		$508K Buy
29,609
+529
+2% +$9.13K 0.01% 816
2018
Q4 		$439K Buy
29,080
+618
+2% +$10.9K 0.01% 786
2018
Q3 		$582K Sell
28,462
-1,195
-4% -$23.8K 0.01% 805
2018
Q2 		$556K Buy
29,657
+1,897
+7% +$35.7K 0.02% 823
2018
Q1 		$534K Buy
27,760
+329
+1% +$6.59K 0.01% 829
2017
Q4 		$538K Buy
27,431
+831
+3% +$16.6K 0.01% 837
2017
Q3 		$572K Buy
26,600
+343
+1% +$7.29K 0.02% 804
2017
Q2 		$548K Buy
26,257
+482
+2% +$9.74K 0.02% 803
2017
Q1 		$499K Buy
25,775
+168
+0.7% +$3.11K 0.01% 797
2016
Q4 		$435K Buy
25,607
+748
+3% +$13.1K 0.01% 854
2016
Q3 		$466K Sell
24,859
-3,485
-12% -$65.7K 0.01% 836
2016
Q2 		$487K Buy
28,344
+547
+2% +$10.1K 0.01% 802
2016
Q1 		$499K Buy
27,797
+1,544
+6% +$28K 0.02% 757
2015
Q4 		$621K Sell
26,253
-16,367
-38% -$406K 0.02% 701
2015
Q3 		$960K Buy
42,620
+671
+2% +$18.8K 0.03% 591
2015
Q2 		$1.18M Sell
41,949
-3,819
-8% -$106K 0.03% 572
2015
Q1 		$1.26M Buy
45,768
+276
+0.6% +$7.53K 0.03% 558
2014
Q4 		$1.13M Buy
45,492
+19,078
+72% +$458K 0.03% 570
2014
Q3 		$583K Sell
26,414
-46
-0.2% -$999 0.02% 790
2014
Q2 		$550K Buy
26,460
+6,114
+30% +$128K 0.02% 823
2014
Q1 		$442K Sell
20,346
-180
-0.9% -$4.01K 0.01% 874
2013
Q4 		$419K Buy
20,526
+386
+2% +$7.49K 0.01% 885
2013
Q3 		$387K Buy
20,140
+2,023
+11% +$38.7K 0.01% 864
2013
Q2 		$324K Buy
+18,117
New +$327K 0.01% 896

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Oppenheimer & Co's HQL Position: Q1 2026 in Review

Oppenheimer & Co increased its abrdn Life Sciences Investors (HQL) stake by 59% in Q1 2026, buying an estimated $109K and bringing the position to 17,494 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

Oppenheimer & Co first reported a position in HQL in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.26M in Q1 2015. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Oppenheimer & Co held 17,494 shares of abrdn Life Sciences Investors worth $285K as of Q1 2026.
  • Oppenheimer & Co bought 6,504 abrdn Life Sciences Investors shares in Q1 2026, an estimated $109K.
  • abrdn Life Sciences Investors made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1424 holding.
  • Oppenheimer & Co first reported a position in abrdn Life Sciences Investors in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's abrdn Life Sciences Investors position peaked at $1.26M in Q1 2015.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.